In the BioHarmony Drug Report Database
Obiltoxaximab
Anthim, Obiltoxaximab SFL (obiltoxaximab) is an antibody pharmaceutical. Obiltoxaximab was first approved as Anthim on 2016-03-18. It is used to treat anthrax, crohn disease, and graft vs host disease in the USA. It has been approved in Europe to treat anthrax.
Trade Name
|
Obiltoxaximab SFL |
|---|---|
Common Name
|
obiltoxaximab |
ChEMBL ID
|
CHEMBL3544926 |
Indication
|
anthrax, crohn disease, graft vs host disease |
Drug Class
|
Monoclonal antibodies: toxin as a target |
Image (chem structure or protein)
